Navigation Links
New research shows genetic test for lung cancer risk prompts smokers to quit
Date:11/8/2010

Philadelphia November 8, 2010 New research shows a gene-based test for lung cancer risk assessment motivates smokers to quit or cut down, according to results of a clinical study presented today at the American Association of Cancer Research's Ninth Annual Conference on Frontiers in Cancer Prevention Research.

Six months after taking the Respiragene test to identify susceptibility for lung cancer risk, 32% of the randomly recruited smokers in the study had quit smoking altogether and a further 48% had reduced their intake of cigarettes. More than half of the smokers taking the risk test (63%) had used nicotine replacement products, the first line therapy recommended to help smokers quit. More than 90% of those who took the risk stratification test said they would recommend it to family and friends who smoked.

"The findings from this research support other studies showing gene-based risk testing of smokers leads to significantly reduced smoking rates," said Dr Robert Young, Associate Professor of Medicine and Molecular Genetics at Auckland University, who presented the study findings. "Current quit rates are pretty dismal. Given the number of lung cancer deaths each year, improving those quit rates must be a priority."

Only about 4% to 7% of people are able to quit smoking on any given attempt without medicines or other help, according to the American Cancer Society.

Lung cancer kills more than 440 Americans a day and more than 157,000 a year. In the United States, lung cancer accounts for nearly 30% of all smoking-related deaths. The single most important action a smoker can take to reduce their risk is to quit smoking. Although the link between smoking and lung cancer is well knownapproximately 90% of lung cancers are diagnosed in current or former smokerssmoking rates remain static in many states in the US despite ongoing public health initiatives.

"We found the results of the study very reassuring," said Dr Young. "The high rate of interest in taking Respiragene shows that smokers want to learn more about their own risk level, and for the vast majority, it helped them take positive steps to quit. These findings exceeded our expectations, especially as the participants in the study were randomly selected, and not specifically seeking support to quit smoking at the time of the study."

Young said he hoped the test, which personalizes risk for smoking-related diseases, would help lower smoking rates in the same way that measuring an individual's cholesterol and taking appropriate preventive steps to cut risk had brought a significant reduction in mortality from heart disease.

About the research

The study identified current smokers from a clinical database and randomly recruited 55 who completed a baseline questionnaire exploring their smoking habits and recent attempts to quit; 46 accepted the offer to take the test. Participants provided a simple cheek swab for DNA analysis and gave information about their family history of lung cancer and any previous diagnosis of Chronic Obstructive Pulmonary Disease (COPD). A week later smokers who underwent testing returned to the clinic for the result. The test estimates risk of lung cancer as moderate, high or very high based on DNA testing and non-genetic factors. Two follow-up interviews took place two weeks and six months after taking the Respiragene test, examining attitudes to the test and changes in smoking behavior. More than half of the smokers taking the risk test opted to use nicotine replacement products. U.S. Department of Health guidelines for doctors recommend nicotine replacement to help smokers quit; studies consistently show that smokers are much more likely to stop smoking if they are motivated and use medication.


'/>"/>

Contact: Ken Li
kli@chempetitive.com
312-532-4675
Chempetitive Group
Source:Eurekalert

Related medicine news :

1. Hebrew University researchers discover expanded role for cancer-causing gene
2. Common Foot Disorders Can Be Inherited, Research Shows
3. ASHG 2010: New research on implications of direct-to-consumer and clinical genetic testing
4. Research Suggests Link Between Handedness and Dyslexia
5. Breakthrough in cancer vaccine research
6. NTU and A*STAR launch joint Ph.D. research program in immunology
7. Film director launches pioneering hearing research
8. New research shows disparities in hospice enrollment are not likely related to access
9. Researchers expand cyberspace to fight chronic condition in breast cancer survivors
10. VA names UCI orthopedic biomedical engineer a senior research career scientist
11. Researchers led by St. Michaels Hospital receive grant to teach new method of CPR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: